Compositions and methods for vaccinating against HSV-2

Abstract

This invention relates to a method for systemic immune activation which is effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in a mammal. The method is particularly effective for protecting a mammal from herpes simplex virus. Also disclosed are therapeutic compositions useful in such a method.

1. An isolated polynucleotide consisting of SEQ ID NOS: 9, 11 and 12, wherein the polynucleotide encodes amino acids of a herpes simplex virus polypeptide. 
     
     
       2. The polynucleotide of  claim 1 , further comprising a heterologous nucleic acid. 
     
     
       3. The polynucleotide of  claim 2 , wherein said heterologous nucleic acid encodes a heterologous polypeptide fused to said amino acids of said herpes simplex virus polypeptide. 
     
     
       4. The polynucleotide of  claim 2 , wherein said heterologous nucleic acid encodes at least 20 contiguous amino acids of a heterologous herpes simplex polypeptide. 
     
     
       5. The polynucleotide of  claim 3 , wherein said heterologous polypeptide comprises a small self assembly polypeptide, and wherein said heterologous polypeptide self assembles into multimers. 
     
     
       6. The polynucleotide of  claim 3 , wherein said heterologous polypeptide is a secretory signal peptide. 
     
     
       7. The polynucleotide of  claim 1 , which is DNA, and wherein said polynucleotide is operably associated with a promoter and contains a stop sequence. 
     
     
       8. The polynucleotide of  claim 1 , which is messenger RNA (mRNA). 
     
     
       9. The polynucleotide of  claim 1 , further comprising an adjuvant wherein said adjuvant comprises GAP-DMORIE and 1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (DPyPE). 
     
     
       10. A method for raising a detectable immune response to a herpes simplex polypeptide, comprising administering to a vertebrate a polynucleotide of  claim 1 , wherein said polynucleotide is administered in an amount sufficient to elicit a detectable immune response to the encoded polypeptide. 
     
     
       11. A method to treat herpes simplex infection in a vertebrate comprising: administering to the vertebrate in need thereof the polynucleotide of  claim 1 , and pharmaceutically acceptable carrier.